TSE:BHC - Bausch Health Companies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$32.00
  • Forecasted Upside: 171.19 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
C$11.80
▲ +0.89 (8.16%)

This chart shows the closing price for BHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

Analyst Price Target is C$32.00
▲ +171.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is C$32.00, with a high forecast of C$0.00 and a low forecast of C$0.00. The average price target represents a 171.19% upside from the last price of C$11.80.

This chart shows the closing price for BHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Bausch Health Companies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/25/2022Royal Bank of CanadaLower Price TargetOutperformC$34.00 ➝ C$32.00
2/1/2022Royal Bank of CanadaLower Price TargetOutperformC$43.00
4/30/2021Royal Bank of CanadaReiterated RatingOutperformC$51.50
2/25/2021BarclaysBoost Price TargetOverweightC$44.00
2/18/2021Royal Bank of CanadaBoost Price TargetNAC$42.00
6/11/2019BarclaysLower Price TargetC$31.00 ➝ C$28.00
2/21/2019BMO Capital MarketsLower Price TargetC$26.00 ➝ C$25.00
8/8/2018Cantor FitzgeraldReiterated RatingOverweight
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
4/6/2022
  • 8 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
6/5/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/5/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Bausch Health Companies logo
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Read More

Today's Range

Now: C$11.80
Low: C$10.74
High: C$11.83

50 Day Range

MA: C$13.87
Low: C$9.14
High: C$26.38

52 Week Range

Now: C$11.80
Low: C$8.91
High: C$37.42

Volume

1,148,956 shs

Average Volume

728,158 shs

Market Capitalization

C$4.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

The following Wall Street analysts have issued stock ratings on Bausch Health Companies in the last twelve months: Royal Bank of Canada.
View the latest analyst ratings for BHC.

What is the current price target for Bausch Health Companies?

0 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is C$32.00, suggesting a possible upside of 171.2%.
View the latest price targets for BHC.

What is the current consensus analyst rating for Bausch Health Companies?

Bausch Health Companies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BHC will outperform the market and that investors should add to their positions of Bausch Health Companies.
View the latest ratings for BHC.

How do I contact Bausch Health Companies' investor relations team?

Bausch Health Companies' physical mailing address is 2150 Saint-Elzear Blvd W, Laval, Quebec H7L 4A8. The company's listed phone number is 514-744-6792. The official website for Bausch Health Companies is www.valeant.com. Learn More about contacing Bausch Health Companies investor relations.